This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1: (currently amended) A compound of Formula I:



wherein

R^1, R^2, R^3 and R^4 are independently

H,

HO,

$R^{13}O$-,

$R^{13}S$,

~~Halogen~~ halogen,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-,

~~$R^{14}S$-~~, or

$R^{15}R^{16}N$-; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$;

wherein one of R^1, ~~R^2~~, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, R^7 and R^8 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, $R^{13}O$-, CF_3-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^7 and R^8 taken together can be C3-C6-cycloalkyl;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-,

$R^{15}CO$-,

$R^{15}R^{16}NCH_2CO$-,

$R^{14}O_2C$-$(CH_2)_n$-,

$R^{15}R^{16}NCO$-$(CH_2)_n$-,

NC-(CH_2)n-,

H,

C1-C6-alkyl,

C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

R^8 and R^9 taken together can be

$-(CH_2)mCH_2(R^{15})NCO-$,

$-(CH_2)mCH_2OCO-$, or

$-(CH_2)mCH_2CH_2CO-$;

R^{10} and R^{11} are independently

H,

$R^{15}R^{16}N-$,

$R^{15}R^{16}N(CR^{17})-$,

$R^{14}HNCO-$, or

$R^{14}CONH-$;

R^{12} is

H,

~~Halogen~~ halogen,

HO,

$R^{13}O-$,

$R^{15}R^{16}N-$,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2-$,

$R^{14}CO-$, or

$R^{14}CONH-$;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10, alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein R^{10} and R^{11} cannot be both H.

Claim 2: (currently amended) The compound of claim 1 of Formula I wherein one of ~~four~~ the substituents of R^1, ~~R^2,~~ R^3 and R^4 must be C1–C3–alkylthio group or C1–C3–alkoxy group, the other substituents are independently H, $R^{13}O-$, ~~$R^{13}S-$~~ $R^{13}S-$, halogen, or C1-C3-alkyl;

R^2 and R^3 taken together can be $-SCH_2S-$, SCH_2O-, or $-OCH_2S-$;

R^9 is

$R^{15}R^{16}NCO-$,

$R^{15}R^{16}NCS-$,

$R^{15}R^{16}N(CR^{17})-$,

$R^{17}OCO-$, ~~or~~

$R^{15}CO-$, or

H;

R^{10} and R^{11} are independently H, H_2N-, or CH_3CONH-; and pharmaceutically acceptable salts thereof.

Claim 3: (previously amended) A composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.

Claim 4: (canceled)

Claim 5: (currently amended) The compound of ~~claim 2~~ claim 1 of Formula I selected from the group consisting of

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-

methyl-3-propylcarbamoyl-7—methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4—methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4—Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl—7—methoxy—5*H*—2,3-benzodiazepine, 1-(4—Aminophenyl)—8—amino—3,5-dihydro—4—methyl-3-propylcarbamoyl-7—methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)—8—amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4—Aminophenyl)—3,5 —dihydro-4-methyl—3—ethylcarbamoyl—8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbomoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)—7—amino —3,5—dihydro-4—methyl—3—acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-

Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3—methylcarbomyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbomoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbomoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamnoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4— Aminophenyl)—3,5—dihydro—4—methyl—3—acetyl—7-methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro—4—methyl—3-methylcarbamoyl—7—methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-51H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3—benzodiazepine, 1—(4—Aminophenyl)-3,5—dihydro-4—methyl—3—butylcarbamoyl-7—methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio—5*H*—2,3—benzodiazepine, 1-(4—Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl—7—methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro—4— methyl—3—ethylcarbamoyl—7—methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)—8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methvlthio-5*H*-2,3-

benzodiazepine, 1-(4-Aminophenyl)—8—amino—3,5—dihydro—4—methyl—3—butylcarbamoyl—7-methylthio—5*H*—2,3—benzodiazepine, 1—(4—Aminophenyl)—3,5—dihydro—4—methyl—3—acetyl—8—methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthiio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1—(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4—methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine.

Claim 6: (previously amended) A composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.

Claim 7: (canceled)

Claim 8: (previously amended) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 9: (canceled)

Claim 10: (currently amended) A method for treating a patient ~~having a disorder associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors~~ suffering from ischemia, epilepsy or stroke, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the ~~disorder~~ ischemia, epilepsy or stroke, a compound of Formula I:



wherein

R^1, R^2, R^3 and R^4 are independently

H,

HO,

$R^{13}O$-,

$R^{13}S$-,

~~Halogen~~ halogen,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-

$R^{14}CONH$-,

$R^{14}NHCO$-,

$R^{14}NHCO_2$-,

$R^{14}OCONH$-,

$R^{14}O_2S$-,

$R^{14}OS$-,

~~$R^{14}S$-, or~~

$R^{15}R^{16}N$-; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$;

wherein one of R^1, ~~R^2,~~ R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, R^7 and R^8 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, $R^{13}O$-, CF_3-, $R^{14}O_2S$-, $R^{14}OS$-, $R^{14}CO$, $R^{14}CO_2$-, $R^{14}O_2C$-, $R^{14}CONH$-, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^7 and R^8 taken together can be C3-C6-cycloalkyl;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS$-,

$R^{15}R^{16}N(CR^{17})$-,

$R^{17}OCO$-,

$R^{15}CO$-,

$R^{15}R^{16}NCH_2CO$-,

$R^{14}O_2C-(CH_2)_n$-,

$R^{15}R^{16}NCO-(CH_2)_n$-,

NC-(CH$_2$)n-,

H,

C1-C6-alkyl,

C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

R^8 and R^9 taken together can be

$-(CH_2)mCH_2(R^{15})NCO-$,

$-(CH_2)mCH_2OCO-$, or

$-(CH_2)mCH_2CH_2CO-$,;

R^{10} and R^{11} are independently

H,

$R^{15}R^{16}N-$,

$R^{15}R^{16}N(CR^{17})-$,

$R^{14}HNCO-$, or

$R^{14}CONH-$;

R^{12} is

H,

~~Halogen~~ halogen,

HO,

$R^{13}O-$,

$R^{15}R^{16}N-$,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2-$,

$R^{14}CO-$, or

$R^{14}CONHO$;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10, alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{17} is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein R^{10} and R^{11} cannot be both H,

in combination with a pharmaceutically acceptable carrier.

Claim 11: (currently amended) The method of claim 10 wherein, in the compound of Formula I, one of ~~four~~ the substituents of R^1, ~~R^2,~~ R^3 and R^4 must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, $R^{13}O$-, ~~$R^{13}S$-~~ $R^{13}S$-, halogen, or C1-C3-alkyl; R^2 and R^3 taken together can be $-SCH_2S$-, $-SCH_2O$-, or $-OCH_2S$-;

R^9 is

$R^{15}R^{16}NCO$-,

$R^{15}R^{16}NCS-$,

$R^{15}R^{16}N(CR^{17})-$,

$R^{17}OCO-$, or

$R^{15}CO-$

H;

R^{10} and R^{11} are independently H, H_2N-, or CH_3CONH-; and pharmaceutically acceptable salts thereof.

Claim 12 (canceled)

Claim 13: (currently amended) The method of ~~claim 11~~ claim 10 wherein the compound of Formula I is selected from the group consisting of

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-

4-methyl-3-acetyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5 -dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbomoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino -3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbomyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbomoyl-8-methoxy-5H-2,3-

benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbomoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamnoyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4— Aminophenyl)—3,5—dihydro—4—methyl—3—acetyl—7-methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro—4—methyl—3-methylcarbamoyl—7—methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-51H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methylthio-5*H*-2,3—benzodiazepine, 1—(4—Aminophenyl)-3,5—dihydro-4—methvl—3—butylcarbamoyl-7—methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio—5*H*—2,3—benzodiazepine, 1-(4—Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl—7—methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro—4— methyl—3—ethylcarbamoyl—7—methylthio—5*H*—2,3—benzodiazepine, 1-(4-Aminophenyl)—8-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methvlthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)—8—amino—3,5—dihydro—4—methyl—3—butylcarbamoyl—7-methylthio—5*H*—2,3—benzodiazepine, 1—(4—Aminophenyl)—3,5—dihydro—4—methyl—3—acetyl—8—methylthio—5*H*—2,

3—benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-S-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,2-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthiio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1—(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-propylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4—methyl-3-butylcarbamoyl-8-methylthio-5*H*-2,3-benzodiazepine.

Claims 14-15 (canceled)

Claim 16: (currently amended) A compound of Formula II:



wherein

R^1 and R^4 are independently

H,

HO,

$R^{13}O$-,

$R^{13}S$-

~~Halogen~~ halogen,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-

$R^{14}CONH$-,

$R^{14}NHCO-$,

$R^{14}NHCO_2-$,

$R^{14}OCONH-$,

$R^{14}O_2S-$,

$R^{14}OS-$,

~~$R^{13}S-$~~, ~~or~~

$R^{15}R^{16}N-$; or

R^2 is one of H, HO, $R^{13}O$, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CO-$, $R^{14}CONH-$, $R^{14}NHCO-$, $R^{14}NHCO_2$, $R^{14}OCONH-$, $R^{14}O_2S-$, $R^{14}OS-$, ~~$R^{13}S-$~~ $\underline{R^{13}S-}$ and $R^{15}R^{16}N-$ when R^3 is one of HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CO-$, $R^{14}CONH-$, $R^{14}NHCO-$, $R^{14}NHCO_2$, $R^{14}OCONH-$, $R^{14}O_2S-$, $R^{14}OS-$, ~~$R^{13}S-$~~ $\underline{R^{13}S-}$ and $R^{15}R^{16}N-$; or

R^2 is one of H, HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CO-$, $R^{14}CONH-$, $R^{14}NHCO-$, $R^{14}NHCO_2$, $R^{14}OCONH-$, $R^{14}O_2S-$, $R^{14}OS-$, ~~$R^{13}S-$~~ $\underline{R^{13}S-}$ and $R^{15}R^{16}N-$ when R^3 is one of H, HO, $R^{13}O$, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CO-$, $R^{14}CONH-$, $R^{14}NHCO-$, $R^{14}NHCO_2$, $R^{14}OCONH-$, $R^{14}O_2S-$, $R^{14}OS-$, ~~$R^{13}S-$~~ $\underline{R^{13}S-}$ and $R^{15}R^{16}N-$; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$; ~~or~~

wherein one of ~~four~~ the substituents of R^1, ~~R^2,~~ R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, R^7 and R^8 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, $R^{13}O-$, CF_3-, $R^{14}O_2S-$, $R^{14}OS-$, $R^{14}CO$, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CONH-$, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{18} and R^{19} are independently

H,

~~Halogen~~ halogen,

C1-C3-alkyl,

$R^{14}O$-,

CF_3-, or

$R^{14}CO_2$-;

R^{20} and R^{21} are independently

H,

$R^{15}R^{16}N$-,

$R^{15}HNC(NH)$- or

$R^{14}CONH$-;

and pharmaceutically acceptable salts thereof;

wherein R^{20} and R^{21} cannot both be H.

Claim 17: (currently amended) The compound of claim 16 of Formula II wherein one of ~~four~~ the substituents of R^1, ~~R^2,~~ R^3 and R^4 must be C1—C3—alkylthio group or C1—C3—alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen, or C1-C3-alkyl;

R^2 and R^3 taken together can be $-SCH_2S-$, $-SCH_2O-$, or $-OCH_2S-$; R^{20} and R^{21} are independently H, H_2N-, or CH_3CONH-; and pharmaceutically acceptable salts thereof.

Claim 18: (previously amended) A composition comprising the compound of claim 17 and a pharmaceutically acceptable carrier.

Claim 19: (canceled)

Claim 20: (currently amended) The compound of ~~claim 17~~ claim 16 of Formula II selected from the group consisting of 1-(4-Aminophenyl)-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methoxy-5*H*-2,3-benxodiazepine, 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-8-methylthio-5H-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine.

Claim 21: (previously amended) A composition comprising the

compound of claim 20 and a pharmaceutically acceptable carrier.

Claim 22: (canceled)

Claim 23:(previously amended) A composition comprising the compound of claim 16 and a pharmaceutically acceptable carrier.

Claim 24: (canceled)

Claim 25: (currently amended) A method for treating a patient ~~having a disorder associated with excessive activation of the α-amino-3-hydroxy-5-methyl-4-isooxazolepropionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors~~ suffering from ischemia, epilepsy or stroke , the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the ~~disorder~~ ischemia, epilepsy or stroke, a compound of Formula II:



wherein

R^1 and R^4 are independently

H,

HO,

$R^{13}O$-,

$R^{13}S$-,

~~Halogen~~ halogen,

C1-C3-alkyl,

CF_3,

$R^{14}CO_2$-,

$R^{14}O_2C$-,

$R^{14}CO$-

$R^{14}CONH$-,

$R^{14}NHCO-$,

$R^{14}NHCO_2-$,

$R^{14}OCONH-$,

$R^{14}O_2S-$,

$R^{14}OS-$,

~~$R^{14}S-$,~~ or

$R^{15}R^{16}N-$; or

R^2 is one of H, HO, $R^{13}O$, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CO-$, $R^{14}CONH-$, $R^{14}NHCO-$, $R^{14}NHCO_2$, $R^{14}OCONH-$, $R^{14}O_2S-$, $R^{14}OS-$, ~~$R^{14}S-$~~ and $R^{15}R^{16}N-$ when R^3 is one of HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CO-$, $R^{14}CONH-$, $R^{14}NHCO-$, $R^{14}NHCO_2$, $R^{14}OCONH-$, $R^{14}O_2S-$, $R^{14}OS-$, ~~$R^{14}S-$~~ $\underline{R^{13}S-}$ and $R^{15}R^{16}N-$; or

R^2 is one of H, HO, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CO-$, $R^{14}CONH-$, $R^{14}NHCO-$, $R^{14}NHCO_2$, $R^{14}OCONH-$, $R^{14}O_2S-$, $R^{14}OS-$, ~~$R^{14}S-$~~ and $R^{15}R^{16}N-$ when R^3 is one of H, HO, $R^{13}O$, halogen, C1-C3-alkyl, CF_3, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CO-$, $R^{14}CONH-$, $R^{14}NHCO-$, $R^{14}NHCO_2$, $R^{14}OCONH-$, $R^{14}O_2S-$, $R^{14}OS-$, ~~$R^{14}S-$~~ $\underline{R^{13}S-}$ and $R^{15}R^{16}N-$; or

R^1 and R^2, or R^2 and R^3, or R^3 and R^4 taken together can be

$-SCH_2S-$,

$-SCH_2O-$,

$-OCH_2S-$,

$-SCH_2CH_2S-$,

$-SCH_2CH_2O-$, or

$-OCH_2CH_2S-$; ~~or~~

wherein one of ~~four~~ the substituents of R^1, ~~R^2,~~ R^3 and R^4 must be C1-C3-alkoxy or C1-C3-alkylthio group;

R^5, R^6, and R^7 are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, $R^{13}O-$, CF_3-, $R^{14}O_2S-$, $R^{14}OS-$, $R^{14}CO$, $R^{14}CO_2-$, $R^{14}O_2C-$, $R^{14}CONH-$, $R^{14}NHCO$; or

R^5 and R^6 taken together can be C3-C6-cycloalkyl;

R^{13} is C1-C3-alkyl;

R^{14} is H or C1-C3-alkyl;

R^{15} and R^{16} are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R^{15} and R^{16} taken together can be C3-C6-cycloalkyl;

R^{18} and R^{19} are independently

H,

~~Halogen~~ halogen,

C1-C3-alkyl,

$R^{14}O$-,

CF_3-, or

$R^{14}CO_2$-;

R^{20} and R^{21} are independently

H,

$R^{15}R^{16}N$-,

$R^{15}HNC(NH)$- or

$R^{14}CONH$-;

and pharmaceutically acceptable salts thereof;

wherein R^{20} and R^{21} cannot both be H.

in combination with a pharmaceutically acceptable carrier.

Claim 26: (currently amended) The method of claim 25 wherein, in the compound of Formula II wherein one of ~~four~~ the substituents of R^1, ~~R^2,~~ R^3 and R^4 must be C1—C3—alkylthio group or C1—C3—alkoxy group, the other substituents are independently H, $R^{13}O$-, $R^{13}S$-, halogen, or C1-C3-alkyl;

R_2 and R_3 taken together can be $-SCH_2S-$, $-SCH_2O-$, or $-OCH_2S-$;

R^{20} and R^{21} are independently H, H_2N-, or CH_3CONH-; and pharmaceutically acceptable salts thereof.

Claim 27 (canceled)

Claim 28: (currently amended) The method of ~~claim 26~~ claim 25 wherein the compound of Formula II is selected from the group consisting of 1-(4-Aminophenyl)-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methylthio-5*H*-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-4-methyl-8-methylthio-5*H*-2,3-benzodiazepine.

Claims 29-30 (canceled)